A new randomized, double sightless, one measure, comparison research from the pharmacokinetics, safety along with immunogenicity involving MB02 (bevacizumab biosimilar) along with reference point bevacizumab in healthful male volunteers.
https://www.selleckchem.com/products/sovleplenib-hmpl-523.html